Last reviewed · How we verify
gastrointestinal stromal tumor gist
Approved treatments
Clinical guidelines
- FDA label — 2L
Sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. - FDA label — 1L
Sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). - FDA label — 1L
Sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- gastrointestinal stromal tumor gist patent landscape — cliff calendar, originator estates, attackable patents
- gastrointestinal stromal tumor gist treatment landscape brief
- gastrointestinal stromal tumor gist treatment updates RSS
Frequently asked questions about gastrointestinal stromal tumor gist
What are the treatment guidelines for gastrointestinal stromal tumor gist?
FDA label publishes guidelines for gastrointestinal stromal tumor gist. 3 guideline references tracked.
Related
- Treatment landscape: gastrointestinal stromal tumor gist patent cliff · gastrointestinal stromal tumor gist CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing